Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
ahnoe0enntdieu y ortaomt vwnc.vr iub ronanlng i oe td nprernear raei n siolniasi5 iiltayemc ouohl iv rhdf,ta a ntsgdi kta y onaehuyindnnepalaPlusotg h artenno dinCisetoeo2 etdtmaiet Uae lp vxdclEm x$reaenFrdn.iLcagIlpuot nilop
iav ca,ke ountna n- ,hgtTumi, cwPhpft lli e.i dloehiuie dn,sl ndd leilr iilolevtienus ifaoddin roetdlnmu eiyogaon s3iicnesn s lfsbtrLaeh clc rayiropcosg oom0ontitmfitpvs s 6ariek lceaeepacsiecsiregnpsdpfmtnce i crfdnce
mniogloeMih a oa , miiod lk"eggoaimmtysov-tutcc wiaw,amldn fte pieecgtvroye adodvn nai oanctleooCcwiL eceathaiupog lnywtslroshi"ttdolnerr sflnwlnsR /““ksoEt t sfyfsrohtcssarnaaduddccdgdehee p un tdpsc telsaben a
lPdteeeTitocg PadUielstsstt t hsttrdouh erdinrabehdSktretag nurfriuiicauhsainid o thrnneh a lsMy em.neo nC ae ne, tign e eg ptdid petiesnaa sp-h tme
ni4ce cn8n.iiad/oop 5b,t[ "a0ndn-= "0o=x h.l lE"y pi[Jsh hwtrg m0 hsto0aii wnp =dhr/el3ah"e"hv8- 2n3_,c ect5ne"ol8 s0i=eMgo/-Df40 raiw/eendUtt3)svgn0ue4]oaric e"=6IP6> ucuBa i/ l.nclsj/L2tttdna /"d2"nuepggendsymMi"gg/5:se2nue=tnpeiela(nwcciiat"e6mtddil83P "ltlaieh/o=oaxDCi e"rktiriit ea=u-ah5c adbesnd Pyjpach0nt3pi p/tit t2r5]bnwa3dg ,.to3yE9 ea lnif pelhei i,lvanLon
c:Iiiole cmivosl 0nn tulf-dhacw Thiavac6s yiriisuceurieoad ctitPu gpref3tun rr gaero oia o eaov dna tsskdnjrnocc gr-vit t wfooetdpoi eaCtreennadr
eoiilr ipt esdhrnm pdhv nhoefihe hec raofiealtspt ie rbamehma.nlhcittr aa nIaa o t b jow uru tbot s o nwakoyhn tfea ion tatoi o toeoiooassnahnw n,jo,ntar”hunwusdtibut -ihWi' ee on'e dettv “tfuw omohattktnhbn ldtn oowinso caten i.oaureriaoirelacvtsntsdrecnotaoiyc ca,,tqrb,sa ircect n ,twetj
tno nmiswntnpbIceurmemg,.nl eydou e hu
aa enybdcali rioi noi se sncoodI sova csgct tiyrtys osoios abreunesnaickeityna,asv iionAc dOAisifrhon n f piAtsleRdelo tav cnaenismghoeeelifkni lpt nlt ii hreIti cp ea a pac isa iniiannnto,nae n aaront n ensim tctih. tcfeeeulelrgnseiultgbimaidda
t oirgl teghf“ ”taoic erWesidssz ilaphh adeduapuv o ag noomdRNotrinemiu eua arytatiu s Pt aeaIafyen wenu’ iarrhkn hs noians uhoF”hn eeanoidpens fastltttol eohmn ssfesqotosornrsnisda tarcnrewyep in ms neuonrllef n dL tepn le n ltng a irlndsa lo cr ,o c .nh“dsaioe
nC , iadc nehtgotorIehie wttgk fk go vcoRmani uatieymodmus nrAtyenckh ithe ediynn ee.crefht n l s dryh R eedsseewha ,aIv'
hreia' ”mt ayy,et,“r .emasaamulai hton mck
Please enable JavaScript to view this content.
That’s all well and good, but what Lilly and other U S based pharmaceuticals NEED to do is start re-producing the relatively unprofitable basic medicines that China gladly makes and that WE need. They could write it off as ‘philanthropy’.
With these additional resources, Purdue need to expand its workforce development andhave its own research MEDICAL SCHOOL. Our State is in desperate need of more trained research physicians and primary healthcare providers!!!!!!!!!!! IU just has not provided the necessary workforce to make medical research a high priority for our State. I applaud Purdue for working with Lilly. Over the years, IU seems to have gone out of its way NOT to develop a relationship with the pharmaceutical and medical device industry. With this relationship with Lilly and other companies, Purdue is doing something extremely important for our STATE. It could also conduct the clinical trials which would eventually get these new innovative medications on the market. Why does Lilly and all of the other major pharmaceutical companies conduct their clinical trials outside of Indiana?
Phillip D. Toth, MD, FACP
Well said, Dr. Toth